M&A

News

Troubled gene therapy player bluebird sold for a song

At risk of defaulting on financial commitments, gene therapy firm bluebird bio has agreed to sell itself to private equity firms at a knockdown price.

News

AstraZeneca builds in China as Cosette buys Mayne

The reporting week has ended with a flurry of M&A as Cosette Pharma and AstraZeneca agree takeover deals.

News

Poolbeg slumps as Hookipa merger is called off

A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.

News

Novartis builds in cardiovascular with $3.1bn Anthos buy

Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.

News

Merck confirms its interest in buying SpringWorks

Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.

News

Ten years on, Roche jettisons InterMune and Esbriet in US

It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now, it's sold the business.

Troubled gene therapy player bluebird sold for a song

AstraZeneca builds in China as Cosette buys Mayne

Poolbeg slumps as Hookipa merger is called off

Novartis builds in cardiovascular with $3.1bn Anthos buy

Merck confirms its interest in buying SpringWorks

Ten years on, Roche jettisons InterMune and Esbriet in US

NHS use of Incyte's anal cancer drug Zynyz backed by NICE

Securing your ROI: Turning post-acquisition integration into...

M&A

Editor's Picks